Streamline Health Solns Q2 2024 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $4.48M Beat $4.33M Estimate
Portfolio Pulse from Benzinga Newsdesk
Streamline Health Solns reported a Q2 2024 GAAP EPS of $(0.05), missing the $(0.04) estimate, but sales of $4.48M beat the $4.33M estimate. Despite the sales beat, both EPS and sales decreased compared to the previous year.
September 11, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Streamline Health Solns reported a Q2 2024 EPS of $(0.05), missing the $(0.04) estimate, while sales of $4.48M exceeded the $4.33M estimate. However, both EPS and sales declined compared to the previous year.
The company's EPS missed analyst expectations, which is typically negative for stock prices. Although sales beat estimates, the year-over-year decline in both EPS and sales suggests potential challenges, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100